Clinical trials: Difficile
C.Difficile Diarrhea
Clostridium Difficile Infection (CDI) in Hematologic Patients.
The microbiology department prospectively generates a data base of all episodes of Clostridium difficile infection (CDI) in the institution, the investigators will analyse the evolution of the episodes and the incidence per…
- Trial name
- NCT03964844
- Testing
- No intervention
- Where
- Spain
- Volunteers
- 450 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Clostridium Difficile Infection (CDI)
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)
This is a prospective, multicenter, randomized, double-blinded, placebo-controlled Phase 3 study of a microbiota suspension of intestinal microbes.
- Trial name
- NCT03244644
- Testing
- RBX2660, Open label RBX2660 (only for confirmed CDI recurrence)
- Where
- 66 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- Rebiotix Inc.
Clostridium Difficile Infection
Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)
606 participants with Clostridium Difficile Associated Diarrhea (CDAD) participated in this study and received either oral vancomycin or CB-183,315 (surotomycin) in a blinded fashion.
- Trial name
- NCT01597505
- Testing
- Surotomycin, Vancomycin
- Volunteers
- 606 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Clostridium Difficile Infections
Molecular Epidemiology of Clostridium Difficile Infections in Children
Objectives: 1. Describe the molecular epidemiology of Clostridium Difficile infection in children in the Chicago area. 2. Determine the clinical spectrum and risk factors for Clostridium Difficile infection secondary to…
- Trial name
- NCT01957761
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Diarrhea
OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)
The purpose of this study is to investigate the safety and perform preliminary clinical evaluation in patients with mild to moderate CDAD.
- Trial name
- NCT00097422
- Testing
- OPT-80
- Where
- United States
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Clostridium Infection
Monoclonal Antibodies in Clostridium Difficile Infection
Immunoglobulin A (IgA), the major mucosal antibody, plays a key role in maintaining diversity of the intestinal microbiota and eliminating intestinal pathogens.
- Trial name
- IgAClostridium (NCT04874623)
- Testing
- Collection of peripheral blood mononuclear cells
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Recurrent Clostridium Difficile Infection
Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection
This is a randomized, open label, comparative, Phase II study to determine which dose of fecal microbiota transplant using Penn Microbiome Therapy (PMT) products is most effective in treating and preventing recurrence of…
- Trial name
- NCT03973697
- Testing
- Penn Microbiome Therapy - 001, Penn Microbiome Therapy - 002, Penn Microbiome Therapy - 003
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pennsylvania
Clostridioides Difficile Infection
Addressing Personalized Needs in Clostridioides Difficile Infection
BEYOND is aiming to demonstrate how by enrichment of the available SPECIFY score, patients at great likelihood for CDI with unfavorable outcome are early detected
- Trial name
- BEYOND (NCT04725123)
- Testing
- Microbiome analysis
- Where
- Greece
- Volunteers
- 153 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Healthy, Clostridium Difficile Infection
The Impact of Proton Pump Inhibitors on the Fecal Microbiome
The investigators hypothesis is that daily use of a proton pump inhibitor (PPI) is associated with significant alterations in the healthy fecal microbiome that are similar to those seen in persons with an initial episode of…
- Trial name
- NCT01822977
- Testing
- omeprazole
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Diarrhea, Clostridium Difficile
Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
The purpose of this study is to determine whether Lactobacillus acidophilus/rhamnosus complex is effective in the prevention of antibiotic-associated diarrhea (AAD) in the elderly.
- Trial name
- NCT01048567
- Testing
- Lactobacillus acidophilus/rhamnosus
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Vancouver Island Health Authority
Inflammatory Bowel Diseases, Clostridium Difficile Infections
Research on Gut Microbiome and Metabolomics Alterations in C.Difficile Infected IBD Patients
The goal of this research is to compare alterations of gut microbiota and fecal metabolomics alterations between inflammatory bowel disease patients infected with or without Clostridioides difficile.
- Conditions
- Inflammatory Bowel Diseases, Clostridium Difficile Infections, Microtia
- Trial name
- NCT05714566
- Testing
- Clostridioides difficile toxin detection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
COVID-19, GastroIntestinal Bleeding
Re-EValuating the Inhibition of Stress Erosions (REVISE) - COVID-19 Cohort Study
Commonly employed medications used in critically ill patients requiring life support include proton pump inhibitors (PPIs). These medications are thought to prevent gastrointestinal (GI) bleeding from stress-induced ulceration.
- Trial name
- NCT05715567
- Testing
- Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- McMaster University
Clostridium Difficile Infection
Effect of Acid Suppression Medication on Pediatric Microbiome
The colonic microbiome is essential in health and disease, and is highly dynamic during the first several years of life. Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are widely used in children, but…
- Trial name
- NCT02016820
- Testing
- Omeprazole (suspension), Lifestyle Modification
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Columbia University
Clostridium Difficile Infection Recurrence
Bezlotoxumab Efficacy and Tolerability in Cancer Patient
Investigation of efficacy and tolerability of bezlotoxumab in patients with cancer diagnosis in terms of preventing CDI recurrence.
- Trial name
- NCT04415918
- Testing
- Bezlotoxumab Injection
- Volunteers
- 132 people
- Sponsor
- The Cooper Health System
Clostridium Difficile
Probiotics for Clostridium Difficile Infection in Older Adults
The purpose of this study is to determine whether a probiotic, when used together with standard treatment, is effective in reducing duration of symptoms and preventing recurrence of infection in older adults with a first episode…
- Trial name
- PICO (NCT01680874)
- Testing
- Probiotic
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Wisconsin, Madison
Bacterial Infections
Hospital Wide Roll-Out of Antimicrobial Stewardship
Dramatic increases in antibiotic utilization in hospitals continue to drive antibiotic resistance among hospital-acquired pathogens. However, 30-50% of the antibiotic use in hospitals is unnecessary or inappropriate.
- Trial name
- NCT01587937
- Testing
- Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics
- Where
- Canada
- Volunteers
- 19,220 people
- Sponsor
- Sunnybrook Health Sciences Centre
Clostridioides Difficile Infection
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
Summit is developing ridinilazole as a novel antimicrobial for Clostridioides difficile Infection (CDI), formerly known as Clostridium difficile Infection, with the goal of demonstrating an improved Sustained Clinical Response…
- Trial name
- Ri-CoDIFy 1 (NCT03595553)
- Testing
- Ridinilazole, Vancomycin
- Where
- 149 sites in United States, Argentina and 12 more
- Volunteers
- 759 people
- Sponsor
- Summit Therapeutics
Clostridioides Difficile Infection, Clostridium Difficile Infection
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days with standard therapy among first time incident…
- Conditions
- Clostridioides Difficile Infection, Clostridium Difficile Infection, Clostridium Difficile Diarrhea, Clostridia Difficile Colitis
- Trial name
- ACT (NCT04305769)
- Testing
- Alanyl-glutamine
- Where
- 2 sites in United States
- Volunteers
- 260 people
- Sponsor
- University of Virginia
Gastrointestinal Bleeding, Stress Ulcers
Stress Ulcer Prophylaxis in the Intensive Care Unit
Stress ulcer prophylaxis (SUP) is standard of care in the intensive care unit (ICU), however the quantity and quality of evidence is low and potential harm has been reported.
- Trial name
- SUP-ICU (NCT02467621)
- Testing
- Pantoprazole, Saline (0.9%)
- Where
- 33 sites in Denmark, Finland and 4 more
- Volunteers
- 3,350 people
- Sponsor
- Dr. Morten Hylander Møller
Clostridium Difficile
AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment
During or after antibiotic treatment, antibiotic residues impair the intestinal microbiota (gut flora) and lead to adverse effects such as the emergence of bacterial resistance or the occurrence antibiotic-associated diarrhoea…
- Trial name
- ANTICIPATE (NCT02896244)
- Testing
- no intervention
- Where
- 34 sites in France, Germany and 4 more
- Volunteers
- 1,007 people
- Sponsor
- MJM Bonten